Last reviewed · How we verify
Daily rifapentine and isoniazid for 4 weeks — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Daily rifapentine and isoniazid for 4 weeks (Daily rifapentine and isoniazid for 4 weeks) — The Aurum Institute NPC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Daily rifapentine and isoniazid for 4 weeks TARGET | Daily rifapentine and isoniazid for 4 weeks | The Aurum Institute NPC | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Daily rifapentine and isoniazid for 4 weeks CI watch — RSS
- Daily rifapentine and isoniazid for 4 weeks CI watch — Atom
- Daily rifapentine and isoniazid for 4 weeks CI watch — JSON
- Daily rifapentine and isoniazid for 4 weeks alone — RSS
Cite this brief
Drug Landscape (2026). Daily rifapentine and isoniazid for 4 weeks — Competitive Intelligence Brief. https://druglandscape.com/ci/daily-rifapentine-and-isoniazid-for-4-weeks. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab